Authors
Latest:
Executive Pay and InnovationHow the need for biopharma innovation extends to questions around executive compensation.
Latest:
The State of Market Insights in PharmaIt's time to take advantage of a nascent technology embrace taking hold among market insights professionals.
Latest:
Going to the EdgeHow a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
Latest:
Going to the EdgeHow a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
Latest:
Going to the EdgeHow a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
Latest:
The Winning Edge in Emerging MarketsHow a strong corporate board can help ignite success in these regions.
Latest:
Electrical Pulses Spark New Ways to Treat Diseases (SPONSORED)Anthony Arnold offers an overview and update of bioelectronic medicine.
Latest:
Polish Bid for Biotech GloryPoland's government is aiming to make the Eastern European country a biotech powerhouse.
Latest:
The Shrinking CMO IndustryExits from the CMO industry are a more recent development that seems to be picking up momentum.
Latest:
FDA, Industry Face Challenges in the Year AheadUnprecedented policy and access issues threaten R&D momentum.
Latest:
FDA Speeds New Guidances to Inform Clinical Research During PandemicThe need for new therapies to treat coronavirus patients has prompted an onslaught of advisories from FDA clarifying how sponsors should assess and implement changes necessary to fit this new reality.
Latest:
Industry Slams Medicare Price Negotiation SchemeRecent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.
Latest:
New Year, Next Steps in Digital TransformationFive predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.
Latest:
January 2017: Small-Company Attention, Big-Company ResourcesGayle Johnston explains what makes CuraScript SD uniquely able to serve its broad range of customers.
Latest:
Balancing Privacy and Access to Health Information in the Age of Big DataThe Expert Determination standard of protecting patient privacy can answer the growing demand for better data for research and analytics in healthcare.
Latest:
From Chaos to Calm: Making Sense of Social MediaMany big pharma companies have been wary of social media. But if you truly want to be customer centric you do need to be in dialogue with your customers - and social media can allow that, writes Will Simpson.
Latest:
Partnering for Holistic SolutionsAs the healthcare landscape evolves, pharmaceutical companies are being driven to embrace new, unique partnerships to go beyond the pill, writes Weng Si Ho.
Latest:
A Brave New World: Optimizing Access in Wake of COVIDThe top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.
Latest:
Compliance and Consistency with FDA Required LabelingRuth Trzcienski's reviews FDA's new Procedural Guidance to help manufacturers ensure consistency with the FDA-required labelling.
Latest:
The Trouble with Pharma Partnerships ... And How to Fix ThemA new approach to reviving industry collaborations.
Latest:
Reducing the Risk of NoncomplianceThe key steps to easing rising complexity and cost factors.
Latest:
Reducing the Risk of NoncomplianceThe key steps to easing rising complexity and cost factors.
Latest:
CMED: The ‘Curupira’ of Brazil’s Pharma MarketOutlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Latest:
CMED: The ‘Curupira’ of Brazil’s Pharma MarketOutlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Latest:
CMED: The ‘Curupira’ of Brazil’s Pharma MarketOutlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Latest:
Minimizing Liability with Export Control ComplianceBrooke Ringel and Eric McClafferty outline steps companies should take to ensure compliance with export controls.
